Skip to content
Aptus Pharma logo

Aptus Pharma

544529 BSE
₹466.50

Close ·

View as Markdown
MCP
Close 4 Nov 2026 ₹466.50 +411.06 +741% 1Y
Start ₹55.44

Key Fundamentals

SMEConsumer DurablesConsumer Discretionary

Price-based figures at the close · TTM

ROCE
30.00%
Debt to Equity
0.31
EPS (TTM)
—
Book Value
₹13.61
Market Cap
—
P/E (TTM)
—
P/B
34.28
ROE
30.50%
Dividend Yield
0.00%
EBITDA
₹7.60 Cr
52W High
₹510.90
52W Low
₹54.40

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

54 Average

Data confidence 81/100

Category scores

Quality
48
Average
Returns, margins, earnings quality 22% weight
Valuation
23
Poor
Cheap vs sector & own history 24% weight
Growth
99
Strong
Sales & profit trajectory 9% weight
Financial Health
72
Strong
Solvency, leverage, coverage 9% weight
Momentum
99
Strong
Trend strength, vol-adjusted 12% weight
Ownership
49
Average
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

2
  • Company has reduced debt.
  • Company has a good return on equity (ROE) track record: 3 Years ROE 40.8%

Weaknesses

4
  • Stock is trading at 34.8 times its book value
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Debtor days have increased from 99.8 to 147 days.
  • Working capital days have increased from 73.4 days to 117 days

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallStrong Bullish4510
OscillatorsNeutral252
Moving AveragesStrong Bullish208

Key readings

RSI (14)
61.86
Neutral
MACD (12,26,9)
25.54
Bearish
SMA (50)
386.96
Bullish
SMA (200)
225.86
Bullish

As of

Growth Rate

From the financial statements below. 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025.

Revenue

Revenue growth by window
3Y+49.62%
1Y+89.58%

Net profit

Net profit growth by window
3Y+189.71%
1Y+49.03%

Operating cash flow

Operating cash flow growth by window
3YOutflow widened by ₹5.42 Cr
1YOutflow widened by ₹3.76 Cr

Operating margin· change in pp

Operating margin growth by window
3Y+11.54 pp
1Y−3.75 pp

Trailing twelve months: Results are not reported for each of the last eight quarters, so there is no trailing-twelve-month figure.

Revenue by year

Revenue by year, ₹ crore
Mar 2023₹13.90 Cr
Mar 2024₹17.81 Cr
Mar 2025₹24.56 Cr
Mar 2026₹46.56 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2023₹0.19 Cr
Mar 2024₹0.80 Cr
Mar 2025₹3.10 Cr
Mar 2026₹4.62 Cr

Half-yearly Results

₹ Cr
544529 half-yearly results, ₹ crore
Particulars Sep 2024Mar 2025Sep 2025Mar 2026
Sales
9.76
14.8
14.38
32.2
Expenses
7.78
11.93
11.45
27.7
Operating Profit
1.98
2.87
2.93
4.5
OPM %
20.29%
19.39%
20.38%
13.98%
Other Income
0
0.08
0.01
0.12
Interest
0.11
0.36
0.43
0.35
Depreciation
0.11
0.15
0.16
0.25
PBT
1.76
2.44
2.35
4.02
Tax %
25.57%
26.23%
25.53%
28.61%
Net Profit
1.31
1.79
1.75
2.87
EPS (₹)
1.05
1.43
1.02
1.67

Profit & Loss

₹ Cr
544529 profit and loss, annual, ₹ crore
Particulars Mar 2023Mar 2024Mar 2025Mar 2026
Sales
13.9
17.81
24.56
46.56
Expenses
13.28
16.27
19.71
39.11
Operating Profit
0.62
1.54
4.85
7.45
OPM %
4.46%
8.65%
19.75%
16%
Other Income
0
0.03
0.08
0.13
Interest
0.14
0.24
0.47
0.8
Depreciation
0.18
0.21
0.27
0.41
PBT
0.3
1.12
4.19
6.37
Tax %
33.33%
28.57%
26.01%
27.47%
Net Profit
0.19
0.8
3.1
4.62
EPS (₹)
0.48
2
2.48
2.69
Div. Payout %
0%
0%
0%
0%

Balance Sheet

₹ Cr
544529 balance sheet, annual, ₹ crore
Particulars Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
0.3
0.3
5
6.86
Reserves
0.67
1.47
1.97
16.49
Borrowings
2.22
5.31
10.36
7.18
Other Liabilities
3.02
2.95
4.59
13.01
Total Liabilities
6.21
10.03
21.92
43.54
Fixed Assets
0.52
0.63
0.99
2.77
CWIP
0
0
0
0
Investments
0
0
0
0
Other Assets
5.69
9.4
20.93
40.77
Total Assets
6.21
10.03
21.92
43.54

Cash Flow

₹ Cr
544529 cash flow, annual, ₹ crore
Particulars Mar 2023Mar 2024Mar 2025Mar 2026
Operating
−0.18
−2.17
−1.84
−5.6
Investing
−0.35
−0.3
−0.54
−6.37
Financing
0.81
2.86
6.68
7.79
Net Cash Flow
0.28
0.38
4.3
−4.19
Free Cash Flow
−0.53
−2.5
−2.46
−7.79
CFO/EBITDA
−10
−119
−15
−59

Ratios

544529 financial ratios, annual
Particulars Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
63.02
68.66
83.82
147
Inventory Days
176
184
285
232
Days Payable
104
72.25
52.89
139
Cash Conversion Cycle
135
180
316
239
Working Capital Days
51.99
67.02
36.41
117
ROCE %
—
26.48%
38.18%
29.96%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Aptus Pharma insights

61 extracted metrics across FY21–FY26.

Shareholding Pattern

As of Sep 2026

  • Promoters 72.89%
  • Public 24.55%
  • Others 2.57%

No promoter shares pledged as of 14 Oct 2026

Change vs previous quarter

Documents

Frequently Asked Questions about Aptus Pharma

What does Aptus Pharma Ltd do?
Incorporated in 2010, Aptus Pharma Ltd is engaged in the business of marketing and distribution of finished pharmaceutical formulations.
Where is Aptus Pharma Ltd (APPL) listed?
Aptus Pharma Ltd trades under code 544529 on the BSE.
Which sector does Aptus Pharma Ltd belong to?
Aptus Pharma Ltd is classified under the Consumer Goods sector, in the Household Appliances industry.
What is the 52-week high and low of Aptus Pharma Ltd?
Over the last 52 weeks Aptus Pharma Ltd has traded between ₹54.4 and ₹510.9 as of 4 Nov 2026.
What is the Return on Equity (ROE) of Aptus Pharma Ltd?
Aptus Pharma Ltd reported a return on equity of 30.50%. Its debt-to-equity ratio is 0.31.

Company Information

Incorporated in 2010, Aptus Pharma Ltd is engaged in the business of marketing and distribution of finished pharmaceutical formulations.

Website aptus-pharma.com
Listed 30 Sep 2025
Face Value ₹10

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/544529.md for Aptus Pharma Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month